Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease
A Phase III Study of the Efficacy and Safety of 3APS in Patients With Mild to Moderate Alzheimer's Disease
Sponsor: Bellus Health Inc. - a GSK company
Listed as NCT00088673, this PHASE3 trial focuses on Alzheimer Disease and remains ongoing. Sponsored by Bellus Health Inc. - a GSK company, it has been updated 8 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jan 2021 — Jan 2024 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Sep 2020 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bellus Health Inc. - a GSK company
For direct contact, visit the study record on ClinicalTrials.gov .